IE
HRMY icon

Israel Englander’s Harmony Biosciences HRMY Stock Holding History

Israel Englander’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,000
Closed -$232K – 6062
2025
Q1 		$232K Buy
+7,000
New +$251K ﹤0.01% 5230
2023
Q1 		– Sell
-14,000
Closed -$771K – 6569
2022
Q4 		$771K Buy
+14,000
New +$770K ﹤0.01% 4404

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's HRMY Position: Q2 2026 in Review

Israel Englander reduced its Harmony Biosciences (HRMY) stake by 66% in Q2 2026, selling an estimated $20M and leaving 319,812 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2131.

Israel Englander first reported a position in HRMY in Q3 2020 and has held it in 23 quarters since. The position peaked at $26.7M in Q1 2026. 324 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Israel Englander held 319,812 shares of Harmony Biosciences worth $11.6M as of Q2 2026.
  • Israel Englander sold 634,547 Harmony Biosciences shares in Q2 2026, an estimated $20M.
  • Harmony Biosciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2131 holding.
  • Israel Englander first reported a position in Harmony Biosciences in Q3 2020 and has held it in 23 quarters since.
  • Israel Englander's Harmony Biosciences position peaked at $26.7M in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.